@article{dfdc053f025849ea87a43562c904ae58,
title = "Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study",
abstract = "Amonafide 300 mg/M2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.",
keywords = "Amonafide, Central nervous system tumors",
author = "Taylor, {Sarah A.} and Cathryn Rankin and Townsend, {Jeannette J.} and Craig, {Johnny B.} and Vance, {Ralph B.} and Solank, {Dilip L.} and Brown, {Thomas D.} and Kurt Jaeckle",
note = "Funding Information: This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA-22433, CA-37429, CA-16385, CA-35995, CA-13238, CA-12644, CA-45560, CA-35431, CA-35117, CA-13612, CA-42777, CA-35261, CA-35090, CA-35178, CA-32734, CA-28862, CA-35128, CA-14028, CA-32102.",
year = "2002",
doi = "10.1023/A:1014488922368",
language = "English (US)",
volume = "20",
pages = "113--115",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",
}